Source MDx test "96% accurate" at predicting low-risk CRPC

US diagnostics developer Source MDx says that its whole-blood RNA  transcript-based Precision Profiles test predicted survival in men with  castration-resistant prostate cancer. In a study of 62 CRPC patients,  the model separated patients into a high-risk group (survival less than  2.2 years) and a low-risk group (survival greater than 2.2 years; log  rank p=0.00083).

The six-gene CRPC Precision Profile was 96% accurate in predicting  low-risk CRPC patients alive at study end and 93% accurate in predicting  high-risk CRPC patients who died prior to study completion, suggesting  that the model may be a powerful tool for stratifying these patients in  clinical trials, the firm said.

The USA's Prostate Cancer Clinical Trials Consortium will begin a  prospective, multisite clinical trial to validate using Source MDx'  six-gene CRPC Precision Profile to stratify aggressive versus  non-aggressive CRPC patients.